Aktis Oncology Inc
AKTS
NASDAQ
Biotechnology
$24.93
USD
+1.14 (+4.79%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.33B
Volume 229.6K
Revenue
—
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
—
TTM
— YoY
Operating Cash Flow
—
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q1 2026 |
|---|---|---|
Revenue | 9.0 | 3.2 |
YoY Growth | — | -64.3% |
Cost of Revenue | 4.7 | 0.0 |
Gross Profit | 4.3 | 3.2 |
Selling, General & Administrative | 6.9 | 5.9 |
Other Operating Expenses | 0.4 | 0.0 |
Total Operating Expenses | 10.0 | 25.9 |
Operating Income | -5.7 | -22.7 |
EBITDA | -4.1 | -22.1 |
Other Income / Expense | -0.0 | -0.0 |
Total Other Income / Expense | -0.7 | 4.4 |
Income Before Income Taxes | -6.4 | -18.3 |
Income Taxes | 0.0 | 0.0 |
Net Income | -6.4 | -18.3 |
Consolidated Net Income / Loss | -6.4 | -18.3 |
Net Income Attributable to Common Shareholders | -6.4 | -18.3 |
Basic EPS | -$0.04 | -$0.38 |
Diluted EPS | -$0.04 | -$0.38 |
Basic Shares Outstanding | 154.4M | 48.6M |
Diluted Shares Outstanding | 154.4M | 48.6M |